Scilex Holding Company Releases Preliminary Unaudited Financial Results For Gross And Net Sales For The Year Ended December 31, 2023; Total Product Gross Sales Were In The Range Of $150M-$155M; Total Product Net Sales Were In The Range Of $46.5M-$52.5M
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company (NASDAQ:SCLX) released preliminary unaudited financial results for 2023, showing significant growth in gross and net sales of their non-opioid pain management products. ZTlido, their flagship product, saw gross sales between $145M-$150M and net sales between $46M-$52M, marking an increase of 51%-56% and 21%-37% respectively from the previous year. Total product gross sales were between $150M-$155M and net sales were between $46.5M-$52.5M, indicating a growth of 56%-61% and 22%-38% respectively. These results are preliminary and have not been reviewed or audited by independent auditors.
January 02, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scilex Holding Company announced preliminary unaudited financial results for 2023, showing robust growth in sales of their non-opioid pain management products, particularly ZTlido.
The preliminary results indicate a strong year-over-year growth in sales, which is typically a positive signal for investors and could lead to a short-term increase in stock price. However, the confidence score is not at the maximum due to the unaudited nature of the results and the possibility that actual results may differ.
CONFIDENCE 75
IMPORTANCE 90
RELEVANCE 100